Evaluating MARIPOSA’s Secondary Analysis in High-Risk Advanced EGFR-Mutant NSCLC: Practical Implications

Opinion
Video

Martin Dietrich, MD, PhD, discusses the secondary analysis from MARIPOSA evaluating first-line amivantamab plus lazertinib in patients with advanced EGFR-mutant NSCLC.

Video content above is prompted by the following:

  • Briefly comment on the secondary analysis from MARIPOSA evaluating 1L amivantamab + lazertinib vs osimertinib in patients with high-risk advanced EGFR-mutant NSCLC.
    • How are you using amivantamab in the 1L and 2L treatment setting?
    • How do you select patients for treatment with amivantamab?
Recent Videos
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Data from the phase 2 SAVANNAH trial may support savolitinib as a new treatment option following standard-of-care osimertinib in EGFR-mutated NSCLC.

Osimertinib/Savolitinib Shows Meaningful Responses in EGFR+ NSCLC

Russ Conroy
October 16th 2024
Article

Data from the phase 2 SAVANNAH trial may support savolitinib as a new treatment option following standard-of-care osimertinib in EGFR-mutated NSCLC.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Patients with non–small cell lung cancer and larger brain metastases may benefit most from the addition of up-front stereotactic radiosurgery to TKIs.

Stereotactic Radiosurgery/TKIs Improves CNS Outcomes in EGFR/ALK+ NSCLC

Russ Conroy
October 11th 2024
Article

Patients with non–small cell lung cancer and larger brain metastases may benefit most from the addition of up-front stereotactic radiosurgery to TKIs.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Data from the LUMINOSITY trial support the application for telisotuzumab vedotin in nonsquamous NSCLC harboring c-Met protein overexpression.

BLA Submitted for Teliso-V in Advanced EGFR Wild-type NSCLC

Russ Conroy
October 7th 2024
Article

Data from the LUMINOSITY trial support the application for telisotuzumab vedotin in nonsquamous NSCLC harboring c-Met protein overexpression.

Neoadjuvant/Adjuvant Nivolumab/Chemo Approved by FDA in Resectable NSCLC

Neoadjuvant/Adjuvant Nivolumab/Chemo Approved by FDA in Resectable NSCLC

Roman Fabbricatore;Ariana Pelosci
October 3rd 2024
Article

Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.